Meeting
2019 ASCO Annual Meeting
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
Authors
Thomas Powles
Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom
Thomas Powles , Joshua J Meeks , Matt D. Galsky , Michiel Simon Van Der Heijden , Hiroyuki Nishiyama , Hikmat Al-Ahmadie , Ashok Kumar Gupta , Jiabu Ye , Sarah E. Donegan , Dana C. Ghiorghiu , Salvatore Ferro , James WF Catto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03732677
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4592)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4592
Abstract #
TPS4592
Poster Bd #
415a
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
First Author: Thomas Powles
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).
First Author: Thomas Powles
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
First Author: Petros Grivas
Poster
2020 ASCO Virtual Scientific Program
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
First Author: Guru Sonpavde